Upstream Bio (NASDAQ:UPB) Posts Earnings Results, Beats Estimates By $0.05 EPS

Upstream Bio (NASDAQ:UPB) announced its quarterly earnings data on Tuesday. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.05, FiscalAI reports. Upstream Bio had a negative return on equity of 43.82% and a negative net margin of 4,718.96%.The company had revenue of $0.77 million for the quarter, compared to the consensus estimate of $0.43 million.

Upstream Bio Trading Down 0.9%

NASDAQ UPB opened at $7.38 on Tuesday. The company has a fifty day simple moving average of $6.83 and a 200 day simple moving average of $10.43. Upstream Bio has a 12-month low of $5.85 and a 12-month high of $33.68. The company has a market cap of $401.35 million, a P/E ratio of -2.58 and a beta of 1.26.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of UPB. BNP Paribas Financial Markets grew its position in Upstream Bio by 110.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,527 shares of the company’s stock worth $123,000 after purchasing an additional 3,430 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Upstream Bio by 71.2% during the 2nd quarter. Bank of America Corp DE now owns 18,031 shares of the company’s stock valued at $198,000 after buying an additional 7,500 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Upstream Bio by 85.4% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,084 shares of the company’s stock valued at $210,000 after acquiring an additional 8,788 shares during the period. The Manufacturers Life Insurance Company bought a new position in Upstream Bio in the 2nd quarter worth about $145,000. Finally, Invesco Ltd. boosted its holdings in Upstream Bio by 6.4% in the 2nd quarter. Invesco Ltd. now owns 16,300 shares of the company’s stock valued at $179,000 after purchasing an additional 985 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms recently commented on UPB. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Upstream Bio in a research note on Monday, August 3rd. HC Wainwright began coverage on Upstream Bio in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 price target on the stock. JPMorgan Chase & Co. cut Upstream Bio from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $35.00 to $8.00 in a report on Friday, June 12th. Finally, Mizuho reduced their price objective on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, May 14th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $33.17.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.